Hologic, Inc. (NASDAQ:HOLX) Receives $87.60 Consensus Price Target from Analysts

Hologic, Inc. (NASDAQ:HOLX) has received an average recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $87.60.

Several analysts have commented on the stock. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Royal Bank of Canada restated a “sector perform” rating and set a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. Stephens reaffirmed an “overweight” rating and issued a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research note on Tuesday. Finally, Evercore ISI boosted their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Tuesday, July 30th.

Hologic Stock Down 0.8 %

Shares of NASDAQ:HOLX opened at $82.00 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. The stock has a market cap of $19.14 billion, a price-to-earnings ratio of 41.84, a P/E/G ratio of 2.53 and a beta of 0.98. The company has a 50 day moving average of $80.36 and a 200-day moving average of $76.92. Hologic has a one year low of $64.02 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period last year, the firm earned $0.93 earnings per share. On average, sell-side analysts forecast that Hologic will post 4.09 earnings per share for the current year.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the transaction, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,280 shares of company stock worth $1,469,973. Company insiders own 1.75% of the company’s stock.

Institutional Trading of Hologic

Several large investors have recently modified their holdings of HOLX. Innealta Capital LLC acquired a new position in Hologic during the second quarter valued at approximately $25,000. iA Global Asset Management Inc. acquired a new position in shares of Hologic during the 1st quarter worth $37,000. Sunbelt Securities Inc. bought a new stake in shares of Hologic during the 2nd quarter worth $37,000. Cranbrook Wealth Management LLC acquired a new stake in Hologic in the second quarter valued at about $47,000. Finally, Mather Group LLC. bought a new position in Hologic in the first quarter valued at about $48,000. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.